Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Inhibitor Combined With Pemetrexed Intrathecal Injection in NSCLC With Leptomeningeal Metastases
NCT06132698Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2023
- Primary completion
- May 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, pembrolizumab, pemetrexed in non-small cell lung cancer (NSCLC), leptomeningeal metastasis (LM), sponsored by West China Hospital of Sichuan University. Started Nov 2023; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)leptomeningeal metastasis (LM)
Beyond the preview
Go deeper on NCT06132698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06132698.